Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

Summary IIn comparison i with i h standard d d therapy, h Candesartan-based therapy • reduced the incidence of MACE by 11%, while not statistically significant. • reduced the incidence of new-onset DM by 63%. • caused a lower incidence of drug-related g AE. • significantly reduced the incidence of MACE by 21% in patients with impaired renal function.
Conclusion • Candesartan-based therapy produced comparable effects to Non-ARB-based standard therapy and was well tolerated in CAD patients with hypertension. hypertension • Furthermore Furthermore, candesartan significantly reduced the incidence of new-onset DM. • The present study provides evidence to support the rationale for candesartan candesartan-based based therapy in CAD patients,particularly in those with chronic kidney di disease.
Page 1 and 2:
Comparison of Candesartan vs Amlodi
Page 3 and 4:
30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 5 and 6:
LIFE Incidence of Diabetes Mellitus
Page 7 and 8:
m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10:
ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55: Medications at at Randomization Ran
Page 56 and 57: Primary Primary Endpoint Cumulative
Page 58 and 59: Candesartan vs vs Standard Standard
Page 60 and 61: Subgroup Subgroup analysis analysis
Page 64: Conclusions Candesartan and Amlodip
Page 68 and 69: % Isolated systolic hypertension 0
Page 70: Predictors of new-onset atrial fibr
show all

Comparison of Candesartan vs Amlodipine Comparison of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?